ALNAQ: AI 评分 44/100 — AI 分析 (4月 2026)

Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company filed for Chapter 11 reorganization in 2022.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Allena Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in oral enzyme therapies for rare metabolic and kidney conditions, including its lead candidate ALLN-346 for hyperuricemia and gout. Currently under Chapter 11 reorganization, the company navigates a challenging financial landscape within the competitive biotechnology sector.

ALNAQ是做什么的？

Allena Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Newton, Massachusetts. The company is dedicated to the discovery, development, and commercialization of oral enzyme therapeutics designed to treat patients suffering from rare and severe metabolic and kidney disorders. Its primary focus has been on addressing unmet needs in these therapeutic areas through innovative enzyme-based solutions. The company's lead product candidate, ALLN-346, is a novel urate-degrading enzyme intended for patients with hyperuricemia and gout, particularly in the setting of advanced chronic kidney disease. This therapy aims to reduce uric acid levels, thereby alleviating the symptoms and complications associated with these conditions. Allena Pharmaceuticals has sought to advance ALLN-346 through clinical trials, with the goal of demonstrating its safety and efficacy for potential regulatory approval and commercialization. However, on September 2, 2022, Allena Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. This event has significantly impacted the company's operations and future prospects, introducing substantial uncertainty regarding its ability to continue development programs and ultimately bring its products to market. The company's future hinges on the successful navigation of the bankruptcy process and the potential for restructuring or acquisition.

ALNAQ的投资论点是什么？

Investing in Allena Pharmaceuticals, Inc. (ALNAQ) presents significant risks due to its Chapter 11 reorganization filing in September 2022. The company's future hinges on its ability to restructure its finances and operations. The primary value driver is ALLN-346, a novel urate-degrading enzyme for hyperuricemia and gout in advanced chronic kidney disease. However, the success of ALLN-346 is uncertain, and the company's financial instability poses a major hurdle. Potential catalysts include successful restructuring and positive clinical trial updates, though these are highly speculative. Investors should carefully consider the high-risk nature of this investment, given the company's financial condition and the inherent uncertainties in pharmaceutical development. The negative beta of -14.54 indicates high volatility relative to the market.

ALNAQ在哪个行业运营？

Allena Pharmaceuticals operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The market for treatments for metabolic and kidney disorders is substantial, driven by the increasing prevalence of conditions such as hyperuricemia, gout, and chronic kidney disease. However, the industry is also highly competitive, with numerous companies developing novel therapies for these indications. Allena's Chapter 11 filing reflects the challenges faced by smaller biotech companies in securing funding and navigating the complex regulatory landscape.

Biotechnology

Healthcare

ALNAQ有哪些增长机遇？

Advancement of ALLN-346: Successful completion of clinical trials and regulatory approval for ALLN-346 could provide significant revenue potential, addressing the unmet needs of patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The market for gout treatments is projected to reach billions of dollars, offering a substantial opportunity if ALLN-346 demonstrates superior efficacy and safety. Timeline for approval is uncertain due to the company's financial situation.
Expansion of Pipeline: Developing additional oral enzyme therapeutics for other rare and severe metabolic and kidney disorders could diversify Allena's product portfolio and reduce reliance on ALLN-346. Identifying new targets and advancing novel therapies through preclinical and clinical development could create long-term value. However, this depends on securing additional funding and resources, which is challenging given the current financial constraints. The timeline for new pipeline development is highly uncertain.
Strategic Partnerships: Collaborating with larger pharmaceutical companies or research institutions could provide access to funding, expertise, and resources to accelerate the development and commercialization of Allena's products. Strategic partnerships could also expand the company's reach and market access. However, attracting partners may be difficult given the company's Chapter 11 status. The timeline for securing partnerships is uncertain.
Restructuring and Recapitalization: Successful completion of the Chapter 11 reorganization process could provide Allena with a fresh start and the opportunity to restructure its finances and operations. Securing new funding or investment could enable the company to continue its development programs and pursue its strategic goals. The timeline for restructuring is dependent on the bankruptcy court and the company's ability to negotiate with creditors.
Orphan Drug Designation: Obtaining orphan drug designation for ALLN-346 or other pipeline candidates could provide regulatory and financial incentives, such as market exclusivity and tax credits. Orphan drug designation can also facilitate the regulatory approval process and increase the commercial attractiveness of the product. The timeline for obtaining orphan drug designation depends on the specific regulatory requirements and the submission of a complete application.

Allena Pharmaceuticals filed for Chapter 11 reorganization on September 2, 2022, impacting its operational and financial stability.
The company's lead product candidate, ALLN-346, targets hyperuricemia and gout in patients with advanced chronic kidney disease.
Allena Pharmaceuticals has a market capitalization of $0.00B, reflecting its distressed financial situation.
The company's P/E ratio is -0.07, indicating negative earnings.
Allena Pharmaceuticals does not offer a dividend, reflecting its focus on research and development and current financial constraints.

ALNAQ提供哪些产品和服务？

Discovers oral enzyme therapeutics.
Develops treatments for rare and severe metabolic disorders.
Develops treatments for rare and severe kidney disorders.
Commercializes oral enzyme therapeutics.
Focuses on unmet needs in specific therapeutic areas.
Lead product candidate is ALLN-346 for hyperuricemia and gout.

ALNAQ如何赚钱？

Develops and patents novel enzyme therapeutics.
Conducts preclinical and clinical trials to demonstrate safety and efficacy.
Seeks regulatory approval from the FDA.
Commercializes approved products through partnerships or direct sales.

Patients with rare and severe metabolic disorders.
Patients with rare and severe kidney disorders.
Healthcare providers who treat these patients.
Pharmacies and hospitals that dispense the company's products.

Patented enzyme therapeutics provide exclusivity.
Focus on rare diseases creates niche market opportunities.
Specialized expertise in enzyme engineering and development.
Orphan drug designation provides market exclusivity and incentives.

什么因素可能推动ALNAQ股价上涨？

Ongoing: Chapter 11 reorganization process and potential restructuring.
Upcoming: Potential for securing new funding or investment.
Upcoming: Clinical trial updates for ALLN-346 (timeline uncertain).

ALNAQ的主要风险是什么？

Ongoing: Chapter 11 bankruptcy and potential liquidation.
Potential: Failure to secure funding and investment.
Potential: Clinical trial failures and regulatory hurdles.
Potential: Competition from other pharmaceutical companies.
Ongoing: Limited financial resources and operational constraints.

ALNAQ的核心优势是什么？

Novel enzyme therapeutics for unmet needs.
Lead product candidate ALLN-346.
Focus on rare and severe diseases.
Potential for orphan drug designation.

ALNAQ的劣势是什么？

Chapter 11 reorganization.
Limited financial resources.
Dependence on a single product candidate.
High regulatory and clinical trial risks.

ALNAQ有哪些机遇？

Strategic partnerships and collaborations.
Expansion of pipeline with new enzyme therapeutics.
Successful restructuring and recapitalization.
Growing market for treatments for metabolic and kidney disorders.

ALNAQ面临哪些威胁？

Competition from other pharmaceutical companies.
Regulatory hurdles and delays.
Clinical trial failures.
Inability to secure funding and investment.

ALNAQ的竞争对手是谁？

Bürgenstock Resort Holdings AG — Focus on hospitality, not pharmaceuticals. — (BUGVF)
Green Innovations Ltd — Focus on eco-friendly products, not pharmaceuticals. — (GRYN)
ImVaq, Inc. — Unknown business model. — (IMVIQ)
Indra Sistemas SA — Focus on technology and consulting, not pharmaceuticals. — (INDR)
LHR Pharma Inc. — Focus on generic pharmaceuticals. — (LHRP)

Key Metrics

MoonshotScore: 44/100

Company Profile

Headquarters: Newton, US
Employees: 12
Founded: 2017

AI Insight

AI analysis pending for ALNAQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Allena Pharmaceuticals, Inc. do?

Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Its lead product candidate, ALLN-346, is a novel urate-degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. However, the company filed for Chapter 11 reorganization in 2022, impacting its operations and future prospects. The company's future depends on successful restructuring.

What do analysts say about ALNAQ stock?

Given Allena Pharmaceuticals' Chapter 11 reorganization and OTC listing, formal analyst coverage is likely limited or non-existent. Key valuation metrics such as price targets and ratings are unavailable. Investment considerations revolve around the potential for successful restructuring, the future of ALLN-346, and the inherent risks associated with distressed companies. Investors should conduct their own due diligence and consider the high-risk nature of this investment. There is no analyst consensus available.

What are the main risks for ALNAQ?

The primary risk for Allena Pharmaceuticals is its Chapter 11 bankruptcy, which could lead to liquidation or significant dilution for existing shareholders. Financial instability, limited resources, and dependence on a single product candidate (ALLN-346) also pose substantial risks. Clinical trial failures, regulatory hurdles, and competition from other pharmaceutical companies further compound the challenges. Investing in ALNAQ carries a high degree of uncertainty and potential for loss.